Dr. Kathryn Lang, vice president of Health Outcomes and Evidence at Guardant Health discusses research highlighting the significance of its LUNAR-2 liquid biopsy test in detecting early-stage colorectal cancer (CRC) with clinically meaningful accuracy. These data were presented during the American Cancer Association for Cancer Research (AACR) Virtual Meeting II in Abstract #2316: “Integrated genomic and epigenomic cell-free DNA (cfDNA) analysis for the detection of early-stage colorectal cancer”.
Dr. Kathryn Lang is a board-certified hemato-oncologist, who completed clinical training in London, U.K. With a strong focus on outcomes research throughout her career and over 50 publications, Dr. Lang moved to an industry role with Pfizer in 2016 where she led the global data science initiatives and developed regulatory grade observational research within Pfizer Oncology. She moved to her current role with Guardant Health in 2018 where she is VP of Outcomes and Evidence focusing on early detection of cancer and applied health economics and outcomes research. She is the principal investigator of ECLIPSE, the prospective, multi-site, observational study which is currently enrolling and aims to recruit 10,000 subjects to provide the clinical validation cohort for the LUNAR-2 colorectal cancer screening assay developed by Guardant Health.